Akari Therapeutics to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial
Rhea-AI Summary
Akari Therapeutics (Nasdaq: AKTX) will present a live video webcast on Tuesday, February 10, 2026 at 1:00 PM EST as part of Webull Financial’s Corporate Connect Webinar Series.
CEO Abizer Gaslightwala will provide a corporate overview of Akari’s ADC platform, the proprietary PH1 spliceosome‑modulating payload, lead program AKTX‑101 (Trop2‑targeting ADC), IND‑enabling activities toward a first‑in‑human trial in late 2026 or early 2027, and a brief update on AKTX‑102.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, AKTX declined 2.22%, reflecting a moderate negative market reaction. Argus tracked a trough of -4.0% from its starting point during tracking. Our momentum scanner triggered 5 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $258K from the company's valuation, bringing the market cap to $11M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
While AKTX trades near its 52-week low with a -1.33% move, several close biotech peers like QTTB, RNTX, KZR, LIXT, and ALLR also show single-day declines ranging from about -1% to nearly -7%, pointing to generally weak sentiment in neighboring names but no clear coordinated sector rotation.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 26 | Patent and pipeline | Positive | -0.5% | Filed provisional patent for AKTX-102 and reiterated PH1 ADC platform plans. |
| Jan 09 | CEO strategic update | Positive | -0.3% | CEO outlined 2025 progress and steps toward clinical transition in 2026. |
| Jan 08 | Conference presentation | Positive | -1.7% | Announced Biotech Showcase presentation on ADC platform and 2026 milestones. |
| Dec 30 | Year-end shareholder letter | Positive | +2.3% | Year-end letter detailed PH1 payload progress and Phase 1 timing goals. |
| Dec 23 | GMP manufacturing start | Positive | -7.1% | Initiated GMP manufacturing of AKTX-101 to support first-in-human trial. |
Recent positive corporate and pipeline updates have often coincided with flat to negative next-day price reactions, suggesting a pattern of selling or indifference into news.
Over the past months, Akari has consistently highlighted progress on its ADC platform and PH1 spliceosome-modulating payload. Updates included initiating GMP manufacturing for AKTX-101, outlining a path to a Phase 1 first-in-human trial in late 2026 or early 2027, and filing a provisional patent for AKTX-102. Multiple investor-focused communications and conference presentations emphasized the oncology repositioning. Despite this, several announcements saw negative or muted one-day price reactions, framing today’s webinar news within a trend of cautious market response.
Regulatory & Risk Context
Akari has an effective S-3 shelf registration filed on 2025-07-29 with recorded usage via at least 2 prospectus supplements, including the 2025-12-17 424B5 offering. Shelf data show remaining capacity of $72,500,000 against cumulative usage of $2,500,000, indicating substantial room for additional registered financings.
Market Pulse Summary
This announcement centers on an investor-focused webinar where management plans to highlight Akari’s ADC platform, PH1 spliceosome-modulating payload, and lead program AKTX-101 with first-in-human studies targeted for late 2026 or early 2027. Recent history shows multiple communications about patents, manufacturing and strategy as the company transitions toward clinical development. Investors may watch for consistency with prior timelines and any additional clarity on development milestones or financing plans disclosed during the presentation.
Key Terms
antibody drug conjugates medical
adcs medical
rna-splicing medical
spliceosome-modulating medical
trop2 medical
ind-enabling regulatory
first-in-human medical
AI-generated analysis. Not financial advice.
– Live video webcast on Tuesday, February 10th at 1:00 PM EST
TAMPA, Fla. and LONDON, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company pioneering next-generation antibody drug conjugates (ADCs) powered by novel RNA-splicing payloads, today announced that it will participate in the Corporate Connect Webinar Series hosted by Webull Financial being held virtually February 10-11, 2026.
As part of the presentation, Abizer Gaslightwala, Director, President and CEO of Akari Therapeutics, will provide a corporate overview highlighting the Company’s next-generation antibody drug conjugate platform and proprietary PH1 spliceosome-modulating payload. He will discuss Akari’s lead program, AKTX-101, a Trop2-targeting ADC designed to deliver PH1 directly to tumors with limited off-target effects, as well as ongoing IND-enabling activities targeting a first-in-human trial in late 2026 or early 2027. Mr. Gaslightwala will also provide a brief update on AKTX-102, an additional ADC program focused on GI and lung cancers.
Details of the presentation are as follows:
Date and Time: Tuesday, February 10, 2026 at 1:00 PM EST
Presenter: Abizer Gaslightwala, Director, President and CEO of Akari
Registration Link: Here
About Webull Financial
Webull Financial is a leading online brokerage platform committed to empowering self-directed investors with innovative tools and cutting-edge technology. With low-cost trading on a wide range of assets, advanced charting tools, and real-time market data, Webull is revolutionizing the way individuals approach investing. The user-centric approach and commitment to staying at the forefront of industry trends underscore the mission to provide a seamless and rewarding experience for traders of all levels. Through the Webull Group, Webull Financial and its affiliates combine to serve tens of millions of users from over 180 countries worldwide. Securities and futures trading is offered to customers by Webull Financial LLC ("Webull Financial"), a broker-dealer registered with the Securities and Exchange Commission (SEC) and a futures commission merchant registered with the Commodity Futures Trading Commission (CFTC). Webull Financial is a member of the Financial Industry Authority (FINRA), the National Futures Association (NFA), and the Securities Investor Protection Corporation (SIPC). All investing is subject to risk, including the possible loss of principal. For more information about Webull, visit www.webull.com.
About Akari Therapeutics
Akari Therapeutics is an oncology biotechnology company developing next-generation antibody drug conjugates (ADCs) with a unique payload, PH1, which targets RNA splicing. Utilizing its innovative ADC discovery platform, the Company has the ability to generate ADC candidates and optimize them based on the desired application to any antigen target of interest. Akari’s lead candidate, AKTX-101, targets the Trop2 receptor on cancer cells and with a proprietary linker, enabling it to deliver its novel PH1 payload directly into the tumor with minimal off-target effects. Unlike current ADCs that use tubulin inhibitors and DNA damaging agents as their payloads, PH1 is a novel payload that is a spliceosome modulator designed to disrupt RNA splicing within cancer cells. This splicing modulation has been shown in preclinical animal models to induce cancer cell death while activating both the innate and adaptive immune system to drive robust and durable activity. In preclinical studies, AKTX-101 has shown to have significant activity and prolonged survival relative to ADCs with traditional payloads. Additionally, AKTX-101 has the potential to be synergistic with checkpoint inhibitors and has demonstrated prolonged survival as both a single agent and in combination with checkpoint inhibitors. The PH1 payload has also been demonstrated to be very active against cancer cells with key oncogenic drivers such as KRAS, BRAF, ARV7, FGFR3 fusions, and others. The Company has initiated IND enabling studies for AKTX-101 with a goal of starting its First-In-Human trial by late 2026/early 2027, and is also advancing AKTX-102, an ADC against a novel target highly relevant in GI and lung cancers. For more information about the Company, please visit www.akaritx.com and connect on X and LinkedIn.
Cautionary Note Regarding Forward-Looking Statements
This press release includes express or implied forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, about the Company that involve risks and uncertainties relating to future events and the future performance of the Company. Actual events or results may differ materially from these forward-looking statements. Words such as “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “future,” “opportunity” “will likely result,” “target,” variations of such words, and similar expressions or negatives of these words are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words. Examples of such forward-looking statements include, but are not limited to, express or implied statements regarding the ability of the Company to advance its product candidates for the treatment of cancer and any other diseases, and ultimately bring therapies to patients. These statements are based on the Company’s current plans, estimates and projections. By their very nature, forward-looking statements involve inherent risks and uncertainties, both general and specific. A number of important factors, including those described in this communication, could cause actual results to differ materially from those contemplated in any forward-looking statements. Factors that may affect future results and may cause these forward-looking statements to be inaccurate include, without limitation: the Company’s need for additional capital; the potential impact of unforeseen liabilities, future capital expenditures, revenues, costs, expenses, earnings, synergies, economic performance, indebtedness, financial condition and losses on the future prospects, business and management strategies for the management, expansion and growth of the business; risks related to global as well as local political and economic conditions, including interest rate and currency exchange rate fluctuations; potential delays or failures related to research and/or development of the Company’s programs or product candidates; risks related to any loss of the Company’s patents or other intellectual property rights; any interruptions of the supply chain for raw materials or manufacturing for the Company’s product candidates, including as a result of potential tariffs; the nature, timing, cost and possible success and therapeutic applications of product candidates being developed by the Company and/or its collaborators or licensees; the extent to which the results from the research and development programs conducted by the Company, and/or its collaborators or licensees may be replicated in other studies and/or lead to advancement of product candidates to clinical trials, therapeutic applications, or regulatory approval; uncertainty of the utilization, market acceptance, and commercial success of the Company’s product candidates; risks related to competition for the Company’s product candidates; and the Company’s ability to successfully develop or commercialize its product candidates. While the foregoing list of factors presented here is considered representative, no list should be considered to be a complete statement of all potential risks and uncertainties. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the SEC, copies of which may be obtained from the SEC’s website at www.sec.gov. The Company assumes no, and hereby disclaims any, obligation to update the forward-looking statements contained in this press release except as required by law.
Investor Relations Contact
JTC Team, LLC
Jenene Thomas
908-824-0775
AKTX@jtcir.com
FAQ
When is Akari Therapeutics (AKTX) presenting at the Webull Corporate Connect Webinar?
What will Akari Therapeutics CEO Abizer Gaslightwala discuss during the AKTX presentation?
What is AKTX‑101 and what clinical timeline did Akari (AKTX) disclose?
Will Akari Therapeutics offer updates on other programs besides AKTX‑101 during the Feb 10 webcast?
How can investors access Akari Therapeutics’ (AKTX) Webull webinar presentation on February 10, 2026?
